Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Sitravatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.87 |
| ▸ | KDR | P35968 | 10/20 | 0.87 |
| ▸ | AXL | P30530 | 4/20 | 0.87 |
| ▸ | FLT3 | P36888 | 2/20 | 0.87 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.87 |
| ▸ | KIT | P10721 | 1/20 | 0.87 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.87 |
| ▸ | MST1R | Q04912 | 11/20 | 0.67 |
| ▸ | MERTK | Q12866 | 2/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | LYN | P07948 | 1/20 | 0.67 |
| ▸ | HCK | P08631 | 1/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.67 |
| ▸ | BCR | P11274 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ABL2 | P42684 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitravatinib SCHEMBL29911094 | 1.00 | MET (0.87) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29514793 | 1.00 | MET (0.87) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL26108676 | 1.00 | MET (0.87) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29927268 | 0.94 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29910958 | 0.94 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL26109867 | 0.94 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29774217 | 0.93 | MET (1.00) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL30276257 | 0.93 | MET (1.00) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29355690 | 0.93 | MET (1.00) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL172015 | 0.93 | MET (1.00) | METKDRAXLFLT3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022192507-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | claimed |
| WO-2022192507-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |